Cinacalcet, fibroblast growth factor-23, and cardiovascular disease in hemodialysis: The evaluation of cinacalcet HCl therapy to lower cardiovascular events (EVOLVE) trial - Moe, S M; Chertow, G M; Parfrey, P S (Circulation, 2015)
et al.